Cytokine storm
A self-amplifying, dysregulated release of inflammatory signaling proteins that overwhelms normal regulation and damages tissue. Implicated in severe COVID-19 pneumonia and a recognized clinical syndrome long before COVID-19.
How researchers study it
"Cytokine storm" entered the medical literature in the 1990s describing graft-versus-host disease, and has since been applied to sepsis, hemophagocytic lymphohistiocytosis, CAR-T cell therapy reactions, and severe viral pneumonias. A widely cited 2020 NEJM review by Fajgenbaum and June lays out a unifying framework — elevated circulating cytokines, immune cell hyperactivation, and systemic inflammation that drives organ dysfunction (Fajgenbaum & June, NEJM, 2020).
In severe COVID-19, researchers consistently measure elevated interleukin-6 (IL-6), interleukin-1 beta, tumor necrosis factor (TNF), and C-reactive protein in plasma from critically ill patients (Huang et al., Lancet, 2020, PubMed 32125452). The pattern partially overlaps with sepsis but has some COVID-specific features, and the field has debated whether the term "cytokine storm" is fully accurate or whether COVID-19 hyperinflammation should be classified separately.
Therapeutically, drugs targeting cytokine signaling have been tested in severe COVID-19. Tocilizumab and sarilumab (IL-6 receptor antagonists) and baricitinib (JAK inhibitor) showed mortality benefit in hospitalized patients on supplemental oxygen in large randomized trials such as RECOVERY and REMAP-CAP — establishing that dampening specific cytokine pathways can improve outcomes in selected patients.
Common misconceptions
- Fajgenbaum DC, June CH. "Cytokine Storm." New England Journal of Medicine, 2020. nejm.org
- Huang C et al. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan." Lancet, 2020. PubMed: 32125452
- RECOVERY Trial. recoverytrial.net